Sera Prognostics, Inc. (SERA)
|Net Income (ttm)||-21.51M|
|Trading Day||July 27|
|Day's Range||8.91 - 9.90|
|52-Week Range||8.91 - 15.50|
SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...
Sera Prognostics, Inc. has filed to go public with an IPO on the NASDAQ.
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk...
The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time
Sera Prognostics is a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our first commercial product, the PreTRM test, is ... [Read more...]
Diagnostics & Research
|IPO Date |
Jul 15, 2021
Gregory C. Critchfield, M.D., M.S.
|Stock Exchange |
|Ticker Symbol |
In 2020, SERA's revenue was $25,000, a decrease of -30.56% compared to the previous year's $36,000. Losses were -$19.85 million, 20.1% more than in 2019.